Prostate cancer is one of the most common cancers in men and a major cause of cancer-related deaths. Yet it is tricky to diagnose - the commonly used PSA test can result in over- diagnosis and unnecessary further procedures. Now, new research led by the University of Adelaide in Australia promises to improve the accuracy of prostate cancer diagnosis with the help of biomarkers in seminal fluid.
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
The Advanta V12 stent (MAQUET) is the company’s proprietary balloon-expandable covered stent technology. Prof. Richard G McWilliams, Radiology Department, Royal Liverpool University Hospital, Liverpool, UK, spoke about his centre’s experience with the Advanta V12.
A study from Lublin, Poland, that set out to evaluate the results of selective catheterisation of occluded fallopian tubes and its effect on fertility was presented at the Global Embolization Symposium and Technologies US (GEST US, 1–4 May, San Francisco, USA) meeting.
Research presented at the Global Embolization Symposium and Technologies US (GEST US meeting, 1–4 May, San Francisco, USA) meeting suggests that patients undergoing transhepatic interventions should have tract embolization performed to prevent haemorrhagic complications.
Over the years, we have seen a rapid development of tools, tricks and techniques that enable ablation of tumours located in regions that are in close proximity to thermally sensitive organs or structures. Despite this, what remains of paramount importance and central to ablating tumours, especially those that are deemed high-risk, is a complete understanding of the type of thermal injury applied, tissue properties of the target organ, electrode design, configuration of the isotherm created when applying one or several of these electrodes and, most importantly, a thorough understanding of anatomical structures that may inadvertently be in the ablative zone.
May 7, 2014—The US Food and Drug Administration (FDA) has issued a Safety Communication regarding removal of retrievable inferior vena cava (IVC) filters. The document, which contains no new safety concerns, updates a previously issued Initial Communication from August 2010 to include information on recently published research and postmarket surveillance studies for these devices.
A study presented at the Society of Interventional Radiology’s (SIR’s) 39th Annual Scientific Meeting (San Diego, USA) by Sam Stuart from Great Ormond Street Hospital for Children, London, UK, suggests that antegrade gastrostomy insertion in infants who are less than 5kg in weight, is technically feasible and safe.
The initial clinical experience is to be presented at the Global Embolization Symposium and Technologies US meeting (GEST US,1–4 May, San Francisco, USA), a press release says.
Preliminary observations from the trial were presented at the Global Embolization Symposium and Technologies US (GEST US meeting, 1–4 May, San Francisco, USA) and show increased tumour penetration with the Surefire system.
Interventional radiology techniques are widely performed and useful in liver metastases from neuroendocrine tumours, but the level of scientific proof is paradoxically low, especially when considering that these techniques are used in patients with cancer, write Maxime Ronot and Valérie Vilgrain.
The US$415 million cash acquisition is expected to strengthen Boston Scientific’s peripheral interventions business and accelerate growth in peripheral atherectomy and thrombectomy categories.
May 30, 2014—Veryan Medical, Ltd. announced that full 2-year data from the MIMICS study were presented at the 15th annual New Cardiovascular Horizons (NCVH) conference in New Orleans, Louisiana.
Seeking a second and third opinion reduced the number of hysterectomies carried out to treat uterine fibroids, according to a single-center study published in the open access Journal of Therapeutic Ultrasound.
A new genetic "signature" to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna heard.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos